Clinicians Trial brief

ATTAIN-MAINTAIN: beyond initial weight loss

Originally posted Dec 2025 · By Joe Zucchi, PA-C, MPAS

Download JPG ↓Original LinkedIn post ↗

1280 × 808 px · PDF includes the original image and a link to this page.

Joe’s commentary

About this visual

An early readout on oral maintenance after injectable incretin treatment.

New Phase 3 data from Lilly’s ATTAIN-MAINTAIN trial highlight an important advance in long-term obesity care.

After achieving weight loss on injectable incretin therapies in SURMOUNT-5, patients who had reached a weight plateau were transitioned to once-daily oral orforglipron for maintenance. At 52 weeks, orforglipron demonstrated superior weight maintenance compared with placebo.

Key findings:
• From Wegovy to orforglipron: average change of +0.9 kg
• From Zepbound to orforglipron: average change of +5.0 kg
• Placebo groups experienced substantially greater weight regain

These results reinforce obesity as a chronic disease that often requires ongoing pharmacologic support. With oral orforglipron under FDA review and oral Wegovy expected soon, it is encouraging to see more long-term treatment options emerging. Now we need to continue making progress regarding cost reduction and coverage improvements to expand access.

My infographic below summarizes the trial design and key results.

Sources & further reading

Original LinkedIn post and discussion ↗

Additional references appear in the infographic and the original LinkedIn discussion.

Related visuals

ATTAIN-MAINTAIN: beyond initial weight loss

Pinch to zoom on touch devices. Open full image ↗